Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
3 April 2012 |
Main ID: |
EUCTR2009-015556-15-IT |
Date of registration:
|
07/06/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis - ND
|
Scientific title:
|
A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis - ND |
Date of first enrolment:
|
07/06/2010 |
Target sample size:
|
1800 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015556-15 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: yes
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Denmark
|
Finland
|
Germany
|
Greece
|
Hungary
|
Italy
|
Netherlands
|
Portugal
|
Slovenia
|
Spain
|
Sweden
|
United Kingdom
| | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Have signed written informed consent 2. Have a diagnosis of relapsing remitting multiple sclerosis as defined by the revised McDonald Committee criteria (Polman 2005). 3. Must have been treated with a stable regimen of either glatiramer acetate (20 mg per day SC) or interferon β-1a (44 mcg 3 times per week) as their principal first therapy for MS for 6 to 18 months prior to randomization. 4. Have had disease activity within 12 months prior to screening while on therapy; 5. Be na?ve to natalizumab. 6. Be between the ages of 18 and 60, inclusive at the time of informed consent. 7. Have a documented EDSS score between 0.0 and 5.5, inclusive. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Have a diagnosis of primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). 2. Have known intolerance, contraindication to, or history of non-compliance with, the use of glatiramer acetate or interferon β-1a. 3. Have had an MS exacerbation (relapse) within 30 days prior to randomization AND/OR the patient has not stabilized from a previous relapse, in the opinion of the Investigator, prior to randomization. 4. The patient is considered by the Investigator to be immunocompromised 5. Subjects for whom MRI is contraindicated, 6. History of any clinically significant (as determined by the Investigator) major disease that would preclude participation in a clinical trial. 7. History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured). 8. Known history of Human Immunodeficiency Virus (HIV). 9. Positive test result for Hepatitis C virus or hepatitis B virus and/or hepatitis B core antibody 10. History of transplantation or any anti-rejection therapy. 11. History of severe allergic or anaphylactic reactions or known drug hypersensitivity. 12. A clinically significant infectious illness (within 30 days prior to screening. 13. History of PML.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1
Level: LLT
Classification code 10063399
|
Intervention(s)
|
Trade Name: TYSABRI Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Natalizumab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-
Trade Name: COPAXONE Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-
Trade Name: REBIF Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-
Trade Name: REBIF*SC 12SIR 6000000UI 22MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22-
|
Primary Outcome(s)
|
Main Objective: The primary study objective is to evaluate the efficacy (clinical and MRI) of switching to natalizumab compared to receiving interferon β1-a or glatiramer acetate.
|
Secondary Objective: The secondary study objective is to evaluate the effect on quality of life of switching to natalizumab compared to receiving interferon β1-a or glatiramer acetate.
|
Primary end point(s): The primary endpoint in this study is the annualized relapse rate in subjects with relapsing remitting multiple sclerosis (RRMS).
|
Secondary ID(s)
|
2009-015556-15-FI
|
101MS325
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|